Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended December 31, 2025, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Company.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt has submitted the Monitoring Agency Report on the use of proceeds raised through its earlier Qualified Institutions Placement (QIP), as required under SEBI's listing and capital issuance rules. The report has been prepared by CRISIL Ratings Limited and has been reviewed and taken on record by the company's Board of Directors and Audit Committee. The filing covers the quarter ended December 31, 2025. This is a routine compliance update and the detailed report from CRISIL would contain the actual utilization status of the QIP funds.
This is a standard regulatory filing and does not indicate any new fundraising or change in business direction. Shareholders should review the attached CRISIL monitoring report to check whether the QIP proceeds are being used as originally disclosed at the time of the issue.